Poor efficacy of haemodiafiltration to treat dabigatran-associated coagulopathy

Journal of the Intensive Care Society

Volumn 15, Issue 2, 2014, Pages 154-157

  Cronin, John ^b   Sivarajaratnam, Mohan ^a  

^a NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^b NONE

Author keywords

Antithrombin; Atrial fibrillation; Dabigatran; Gastrointestinal haemorrhage; Oral anticoagulants

Indexed keywords

BISOPROLOL; DABIGATRAN; LANSOPRAZOLE; PROSTACYCLIN;

AGED; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CASE REPORT; CLINICAL EXAMINATION; COLONOSCOPY; DIGITAL RECTAL EXAMINATION; FEMALE; FOLLOW UP; GASTRIC ULCER BLEEDING; HEART ATRIUM FIBRILLATION; HEMODIAFILTRATION; HUMAN; INTENSIVE CARE; VENOUS THROMBOEMBOLISM; VERY ELDERLY;

EID: 84899421789     PISSN: 17511437     EISSN: None     Source Type: Journal    
DOI: 10.1177/175114371401500214     Document Type: Article

References (16)

1. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2010;361:1139-51.
2. National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. London: NICE 2012;TA249.
3. National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. London: NICE 2008;TA157.
4. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor Dabigatran Etexilate. Clin Pharmacokinet 2008;47:285-95.
5. Boehringer Ingelheim Limited. Summary of product characteristics: Pradaxa 150 mg hard capsules. eMC (Online). 2013. Available from: http://www.medicines.org.uk/EMC/medicine/24839/SPC/Pradaxa+150+mg+hard+capsules Accessed 16th August 2013.
6. Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemostasis 2009;7 (Suppl 1):107-10.
7. Kaatz S, Kouides PA, Garcia DA et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87 (Suppl 1): S141-45.
8. Mahan CE, Fanikos J. New antithrombotics: The impact on global health care. Thromb Res 2011;127:518-24.
9. Warkentin TE, Margetts P, Connolly SJ et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012;119:2172-74.
10. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013;61:487-89.
11. Perez A, Thompson L, Merls GJ. Management of intracranial bleeding associated with dabigatran use in a neurosurgical hospital. Vasc Med 2013;18:169.
12. Liesenfeld K-H, Staab A, Hartter S et al. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet 2013;52:453-62.
13. Thrombin Time. Practical Haemostasis (Online). 2013. Available from: http://www.practical-haemostasis.com/Screening%20Tests/tt.html Accessed 16th August 2013.
14. Stangier J, Rathgen K, Stahle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.
15. Cutler RE, Forland SC, Hammond PGS, Evans JR. Extracorporeal removal of drugs and poisons by hemodialysis and hemoperfusion. Ann Rev Pharmacol Toxicol 1987;27:169-91.
16. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemostasis 2009;15:9S-16S.